中医药

Search documents
政策引领中医药高质量发展 以岭药业全产业链创新显成效
Ren Min Wang· 2025-05-06 06:08
Group 1 - Yiling Pharmaceutical actively responds to national policies and drives the upgrade of the traditional Chinese medicine industry through full industry chain innovation practices, achieving significant results in quality control, technological innovation, and international layout [1][3] - The company adopts a "company + base + farmer" model for the cultivation of medicinal materials, establishing over 60 standardized bases across seven major medicinal material production areas in China, covering more than 700,000 acres and over 40 varieties [1] - Yiling Pharmaceutical's quality control laboratory is equipped with advanced instruments, and has maintained a 100% annual inspection pass rate for its products, demonstrating its commitment to stringent quality standards [1][2] Group 2 - Research and innovation are core driving forces for the company's development, with R&D investment reaching 13.94% in 2024, significantly higher than the industry average [2] - The company has launched 17 patented traditional Chinese medicines, with 11 included in the national medical insurance directory and 5 in the national essential drug list, addressing major diseases such as cardiovascular and respiratory conditions [2] - Yiling Pharmaceutical has established international collaborations with institutions like Leiden University and Cardiff University, publishing over 300 SCI papers and promoting the global dissemination of traditional Chinese medicine culture [2][3] Group 3 - The company's practices span the entire industry chain of traditional Chinese medicine, showcasing a development philosophy of "inheriting the essence and maintaining innovation" [3] - The implementation of national policies is expected to usher in a golden period of high-quality development for the traditional Chinese medicine industry, with Yiling Pharmaceutical's efforts enhancing its competitiveness and driving industry improvement [3][5]
刘宁在郑州走访慰问青年团队代表
He Nan Ri Bao· 2025-05-04 10:36
五四青年节当天,省委书记刘宁在郑州市走访慰问青年团队代表,代表省委、省政府向全省广大青年和青年工作者致以节日问候,希望大家深入学习贯彻习 近平总书记关于青年工作的重要思想,坚定不移听党话、跟党走,挺膺担当、砥砺奋进,不负青春、无愧时代,为谱写中国式现代化河南篇章贡献青春力 量。 省领导安伟、陈星、宋争辉参加。(记者 刘婵 马涛/文 董亮/图) 责任编辑: 路娇 在中原动力智能机器人有限公司,刘宁与青年科研团队深入交流,询问视觉智能分析、人机交互等技术研发进展。"习近平总书记近日在上海考察时指出, 人工智能是年轻的事业,也是年轻人的事业。"刘宁说,要牢记殷切嘱托,永葆青春活力,瞄准科技前沿和市场需求,拓宽应用场景,开发可靠的量产制造 工艺,让更多"青春智慧"转化为现实生产力。在郑州地铁会展中心站,刘宁察看青年主题地铁站"最美地铁口"、志愿服务站等,了解青年发展型城市建设工 作,沿进站通道察看车站人流、安检并乘坐地铁。他强调,要以青年需求为导向,优化公共服务,提高交通设施便民度、安全性,打造年轻人近悦远来的逐 梦之城、向往之地,让青年和城市发展实现双向奔赴。 刘宁还来到河南中医药大学呼吸疾病中医药防治省部共建协同 ...
共启产业高质量发展行动 第五届中国·寿仙谷灵芝文化节在杭启幕
Zhong Guo Jin Rong Xin Xi Wang· 2025-05-01 13:08
转自:新华财经 "穿越"皇家养生圣地 沉浸式体验灵芝文化 本届寿仙谷灵芝文化节巧妙融合了传统中医药文化与现代互动体验,通过"中医文化展示+宋韵游园+趣味打卡"创新形式,让参与者在移步换景间感受灵芝 文化的深厚底蕴。 在慈福宫前的中医药创意文化市集上,灵芝宋韵四雅成为亮点,不仅能喝到新晋网红饮品灵芝咖啡,吃到美味的药膳美食,还能玩到各种别具特色的传统娱 乐项目……同时,还有DIY香囊、定制如意手串等精彩国潮文创,吸引了不少网红达人打卡互动。 "宋韵雅宴"以《仙草降世》《白蛇情劫》《神农百草·以身试药》等艺术表演,再现了灵芝在传统文化中的传奇色彩。以灵芝入馔创新宋宴,诠释"古方今 饪"的跨界魅力,"曲水流觞飞花令"则让嘉宾在诗词歌赋中感受灵芝文化的深厚底蕴。 "白娘子"现场分享 "健康天团"共话灵芝文化 以"德寿"为名,以灵芝为脉。活动现场,与寿仙谷结缘的六位"跨界嘉宾",共话古今,开启了一场温情沙龙。 4月30日,第五届中国·寿仙谷灵芝文化节在杭州南宋德寿宫启幕。本届灵芝文化节以文化市集、启幕盛典、宋韵雅宴三大篇章展开,来自中医药、科研、体 育、电商等各界嘉宾齐聚一堂,展现了灵芝产业"承古法、立新章"的蓬勃气象 ...
广西东兰县:锚定10亿目标 中草药产业“绿叶”变“金叶”
Zhong Guo Jing Ji Wang· 2025-05-01 00:03
田地里套种的玉米和山乌龟均长势良好。记者杨秀峰摄 王秀玉高兴地说,"采摘药材每天收入100元,田地有租金,还可以种植水稻,一年能增收1万多元。" 暮春时节,广西壮族自治区东兰县武篆镇红里村天然中草药种植基地一片片岩黄连正在盛开,犹如黄色花海在风中摇曳,王秀玉等村民正忙着收割,并将种 子挑选出来。 村民忙着采收中草药岩黄连。记者 杨秀峰摄 "岩黄连生长在喀斯特石缝中,过去靠村民采挖,产量低、破坏生态。如今我们通过组培育苗、仿野生种植,亩产从30公斤提升至200公斤,带动全县累计种 植面积超5000亩。"广西中小企业联合会会长、广西河丰药业有限责任公司创始人、福旺国医堂创始人唐恢天向记者表示:"我们还根据岩黄连的生长周期, 发明了药粮套种模式,每年11月播种岩黄连,来年4月采收后农民开始种植水稻,实现'一地多收'"。 走进红里村,药粮套种、轮种的景象随处可见,稻田里轮种着岩黄连,玉米田中套种着山乌龟,林下复种着草珊瑚。据唐恢天介绍,这些种植模式效益十分 显著。除去粮食作物的收成,每亩岩黄连能产出鲜品500公斤,产值可达2.5万元,且半年就能收获一次;山乌龟每亩鲜品产量高达5000公斤,产值5万元, 三年收获一次; ...
成都发布中医药产业支持政策清单2.0版,港澳台携手蓉城建立联动长效机制
Sou Hu Cai Jing· 2025-04-30 05:42
Group 1 - The Chengdu Traditional Chinese Medicine (TCM) Industry Circle Strengthening Conference was held on April 29, 2025, focusing on the theme of "integrated empowerment for efficiency enhancement and shared quality development" [1] - The updated Chengdu TCM Industry Support Policy List (version 2.0) was released, which aims to promote collaborative and shared development of the TCM industry ecosystem [3] - Chengdu has established itself as a significant hub for TCM, with 3,394 TCM medical institutions and 126 large-scale enterprises, achieving an industry scale exceeding 30 billion yuan [3] Group 2 - The new policy list emphasizes comprehensive coverage of the entire TCM industry chain, addressing pain points for enterprises, and enhancing technological integration [3] - A long-term collaborative mechanism with Hong Kong, Macau, and Taiwan was initiated to promote TCM internationalization, focusing on standard recognition and resource sharing [5] - A total of 65 supply-demand items were identified, covering areas such as medicinal material cultivation, technology research and development, and medical cooperation [5] Group 3 - The conference featured a roadshow segment to facilitate direct information exchange between enterprises and promote collaboration in TCM technology innovation [6] - Future initiatives will include building precise platforms, strengthening policy support, and facilitating international market access for TCM enterprises [8] - A signing ceremony was held for 20 enterprises across various fields, including TCM manufacturing, research, and health care [9]
记者探访澳门大学实验室:人工智能赋能中药高质量发展
Zhong Guo Jing Ji Wang· 2025-04-30 03:05
走进实验室,映入眼帘的既有中药煎壶、捣药罐等传统容器还有药物递送模拟器、胶囊填充机等设备。 近年来,实验室也在探索重点交叉学科研究领域,其中就包括中药+人工智能(AI)。澳门大学中华医药 研究院副院长路嘉宏表示,要推进中药高质量发展,离不开中药与先进技术的结合。 "过去我们进行百万计的小分子筛选可能需要十年时间。在引入人工智能技术替代人工筛选后,数十秒 就完成了同样工作,研究院所使用的人工智能技术正是与内地的一家企业合作的。"路嘉宏说。 28日下午,"机遇湾区""机遇香港""机遇澳门"采访团来到中药质量研究国家重点实验室(澳门大学)。 过去数年,实验室取得了多项重大突破,建立了中药化学、质量分析、生物活性质量监督、安全质量检 定、中药制药和中药质量评价等六个具有国际水平的关键技术平台。陈新说:"我们希望通过高质量的 中医药科学研究和成果转化,为人类的健康和福祉作出贡献。"(经济日报记者陈蓉蓉常理) 中药质量研究国家重点实验室(澳门大学)于2010年正式成立,是国家首个中医药领域的国家重点实验 室。多年来以中药质量为核心科学问题,推动中医药标准化、国际化和现代化。实验室以中药质量的评 价为研究方向,以中医药创新 ...
以岭药业24年度关键财务指标持续改善 25Q1盈利逐步提升
Quan Jing Wang· 2025-04-30 00:53
Core Viewpoint - In 2024, Yiling Pharmaceutical (002603) faced competitive pressure in the pharmaceutical industry and adhered to a strategy focused on "standardization, professionalism, health, sustainability, and leapfrogging," aiming for brand success, scale formation, goal achievement, and profit creation [1] Financial Performance - In 2024, Yiling Pharmaceutical reported revenue of 6.513 billion yuan, a year-on-year decrease of 36.88%, and a net profit attributable to shareholders of -0.725 billion yuan, down 153.57% [2] - The decline in performance was attributed to the expiration of certain respiratory products, leading to reduced sales and inventory impairment losses, alongside rising raw material costs and sustained high R&D investments [2] - Despite the net loss, operating cash flow significantly improved, reaching 0.611 billion yuan, a year-on-year increase of 293%, with Q4 cash flow alone at 0.288 billion yuan, up over 26 times [2] - Accounts receivable decreased significantly, with a reduction of 1.176 billion yuan, a drop of 50%, and total liabilities decreased to 3.117 billion yuan, down 24.24 billion yuan or 43.75%, resulting in a debt-to-asset ratio decline of nearly 10 percentage points to 23.4% [2] R&D Investment - Yiling Pharmaceutical maintained a strong focus on R&D, with expenses reaching 0.908 billion yuan in 2024, accounting for 13.94% of revenue, reinforcing its leadership in traditional Chinese medicine innovation [3] - The company developed 17 innovative traditional Chinese medicines targeting eight major clinical disease systems, achieving industry leadership in cardiovascular and respiratory disease treatments [3] - New drug approvals included a treatment for allergic rhinitis and a new drug for gallbladder inflammation, with several patented traditional medicines included in the new medical insurance directory [3] Market Expansion and Strategic Initiatives - Yiling Pharmaceutical has registered products in over 50 countries and regions, actively entering the biopharmaceutical and health sectors, with recent approval for a breast cancer treatment [4] - Continuous R&D investment is expected to enhance product offerings and market share, while the transformation of technological innovations will improve product structure and competitiveness [4] - The company’s strategic focus on R&D and market trends positions it for greater growth in the pharmaceutical market [4] 2025 Outlook - In Q1 2025, Yiling Pharmaceutical reported revenue of 2.358 billion yuan and a net profit of 0.326 billion yuan, reflecting a year-on-year increase of 7.25% [5] - The company’s operating cash flow reached 0.34 billion yuan, nearly doubling year-on-year, with gross margin increasing by 2.34 percentage points to 53.82% [5] - The company aims to enhance its innovation capabilities, accelerate drug development, and implement a brand strategy while optimizing operational management and cost control [6]
ST百灵2024年扭亏为盈
Xin Jing Bao· 2025-04-29 07:11
渠道建设方面,贵州百灵推进营销模式改革,截至目前已完成对贵州、云南、四川等15个省区的直营制 调整,并持续推动营销数字化转型升级,百灵数字销售中控管理系统及数字化销售业务平台已正式上线 运营。今年一季度,贵州百灵医药物流园正式开园运营,该园区可支撑年50亿元规模的药品、医疗器械 及设备流通需求,持续强化公司全产业链布局。 近年来,中医药逐渐走出国门,贵州百灵亦在其中。报告期内,公司银丹心脑通软胶囊已在巴西、新加 坡获得药品注册,并即将获得印度尼西亚、中国香港等国家和地区的注册;今年3月,贵州百灵还与土 库曼斯坦凯伊可可拉公司签订《中药产品代理销售合同》。 研发是企业发展的驱动力,贵州百灵正逐渐步入新药研发的收获期。报告期内,公司重点研发项目糖宁 通络片成为《中药注册管理专门规定》实施以来,首个依托人用经验直接进入Ⅲ期临床试验的中药新 药,目前Ⅲ期临床研究已启动,新药上市步伐持续加快;今年4月,黄连解毒丸完成Ⅲ期临床试验,进 入上市冲刺阶段,获批后将实现我国"证候类"中药新药零的突破,为上百种实热火毒相关疾病提供治疗 新选择。除上述项目外,BD-77、芍苓片、益肾化浊颗粒、冰莲草含片、普依司他等多项创新成果蓄势 ...
中国黑莓深加工产品药效研究获国际认可,百汇园黑莓小镇科研成果将登《世界中医药》期刊
Zhong Guo Chan Ye Jing Ji Xin Xi Wang· 2025-04-29 04:26
中国仪征,2025年4月——中国黑莓产业迎来历史性突破!百汇园黑莓小镇与江苏省中医药研究院联合开展的"黑莓原液+冻干粉"药理学研究成果,即将发表 于国际权威学术期刊《世界中医药》。这是全球首次针对黑莓深加工终端产品的系统性医学研究,标志着中国在黑莓功能价值开发领域实现从"营养分 析"到"精准干预"的跨越式发展。 跨越式突破:从果实到产品的医学实证 长期以来,国际学术界对黑莓的研究多聚焦于鲜果营养成分,对其深加工产品的药效机制研究始终处于空白。研究团队以百汇园自主研发的"黑莓原液""黑 莓冻干粉"为样本,通过动物实验与高分辨质谱分析,首次揭示深加工技术对活性成分的关键提升: 生物利用率提升:氨基酸、黄酮类等核心成分经工艺优化后,吸收效率显著提高 双重健康价值:证实产品可有效抑制炎症因子表达、调节脂质代谢通路 科学背书:建立"成分-机制-功效"完整证据链,为功能宣称提供医学级支撑 权威背书:产学研融合典范 作为研究合作方的江苏省中医药研究院,其课题组负责人指出:"这项研究具有双重创新价值:既通过现代药理学手段验证传统药食同源理念,又为慢性病 预防提供天然解决方案。" 团队依托百汇园三大核心优势—— 1.20年种质 ...
抢占消费者心智,天士力挖掘医药零售市场增长新动能
Di Yi Cai Jing· 2025-04-29 00:00
Core Insights - The 2025 Wuzhen Health Conference recognized Tianshili (600535.SH) as a VIP strategic partner and awarded its products for innovation and popularity in the retail market [1] - The Chinese pharmaceutical retail market is projected to reach 501.9 billion yuan in 2024, driven by policy changes and demographic shifts [3] - Tianshili focuses on integrating traditional Chinese medicine with modern medical practices, targeting major disease areas such as cardiovascular, digestive, oncology, and central nervous system disorders [3][8] Company Strategy - Tianshili is transitioning from high-quality products to strong brand recognition, emphasizing a digital marketing system centered on health value [4] - The company employs various promotional strategies, including social media campaigns and educational initiatives, to enhance brand visibility and consumer engagement [5] - Tianshili collaborates with offline strategic partners to create specialized health centers, improving customer service and market penetration [7] Product Performance - In 2024, Tianshili's traditional Chinese medicine segment generated 6.024 billion yuan, with key products like Compound Danshen Dripping Pills and Yangxue Qingnao Granules showing significant sales growth [7] - The company has a robust pipeline for cardiovascular drugs, with ongoing clinical trials for 17 modern Chinese medicine products [10] - Tianshili's innovative products, such as Shao Ma Zhi Jiao Granules and Kun Xin Ning Granules, have received recognition in clinical guidelines, enhancing its market position [10] Innovation and Responsibility - Tianshili emphasizes the integration of modern technology with traditional Chinese medicine to enhance product efficacy and market competitiveness [8] - The company aims to create a three-dimensional innovation system that combines clinical value, digital technology, and patient services [10] - Tianshili's commitment to innovation is reflected in its continuous development of new products and improvement of existing ones, ensuring long-term sustainability [10]